Efficacy and Safety of extended-release oral opioid for cough in idiopathic pulmonary fibrosis: A systematic review and meta-analysis of randomized controlled trials
Keywords:
cough, idiopathic Pulmonary Fibrosis (IPF), opioidAbstract
Background and aim: Patients with idiopathic pulmonary fibrosis (IPF) experience a high burden of cough. Currently, no established effective therapy exists for cough in IPF. The overall evidence base of oral extended-release (ER) opioid therapies in this population remains limited. This study aimed to compare the efficacy and safety of ER oral opioids versus placebo for cough in patients with IPF.
Methods: PubMed, Embase, Cochrane, and ClinicalTrial.gov databases were reviewed for randomized controlled trials (RCTs). The primary outcome was 24-hour objective cough frequency. Secondary outcomes included Evaluating Respiratory Symptoms-Idiopathic Pulmonary Fibrosis (E-RS IPF) cough subscale score, Cough Severity-Numeric Rating Scale (CS-NRS) score. Safety outcomes included serious adverse events and adverse events leading to discontinuation.
Results: Three RCTs, including 250 patients, were analyzed. Opioid interventions included ER nalbuphine and morphine. ER opioid statistically significantly improved 24-hour objective cough frequency (GMR 0.46; 95% CI 0.23 to 0.92; p = 0.029), CS-NRS score (MD -1.69; 95% CI -2.55 to -0.84; p < 0.001), and E-RS IPF cough subscale score (MD -0.49; 95% CI -0.89 to -0.09; p = 0.016), compared with placebo. No statistically significant differences were observed for serious adverse events or adverse events leading to discontinuation.
Conclusions: ER oral opioids significantly improved cough frequency and patient-reported cough severity and discomfort in patients with IPF, without a significant increase in serious adverse events or treatment discontinuation. Extended-release opioids may be cautiously considered as a therapeutic option for cough in patients with IPF.
References
1. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389: 1941–52. doi:10.1016/S0140-6736(17)30866-8
2. Saunders P, Wu Z, Fahy WA, et al. The burden and impact of cough in patients with idiopathic pulmonary fibrosis: An analysis of the prospective observational PROFILE study. Ann Am Thorac Soc. 2023;20: 1267–1273. doi:10.1513/AnnalsATS.202302-174OC
3. Uzer F, Cilli A, Hanta I, et al. Assessment of quality of life in IPF Patients: a multicenter observational study. Sarcoidosis Vasc Diffuse Lung Dis. 2024;41: e2024043. doi:10.36141/svdld.v41i3.15805
4. Ryerson CJ, Abbritti M, Ley B, Elicker BM, Jones KD, Collard HR. Cough predicts prognosis in idiopathic pulmonary fibrosis: Cough predicts prognosis in IPF. Respirology. 2011;16: 969–75. doi:10.1111/j.1440-1843.2011.01996.x
5. Wu Z, Spencer LG, Banya W, et al. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial. Lancet Respir Med. 2024;12: 273–80. doi:10.1016/S2213-2600(23)00432-0
6. Jones RM, Hilldrup S, Hope-Gill BD, Eccles R, Harrison NK. Mechanical induction of cough in Idiopathic Pulmonary Fibrosis. Cough. 2011;7: 2. doi:10.1186/1745-9974-7-2
7. Harrison NK. Idiopathic pulmonary fibrosis: a nervous cough? Pulm Pharmacol Ther. 2004;17: 347–50. doi:10.1016/j.pupt.2004.09.029
8. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370: 2071–82. doi:10.1056/NEJMoa1402584
9. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370: 2083–92. doi:10.1056/NEJMoa1402582
10. Richeldi L, Azuma A, Cottin V, J, et al. Nerandomilast in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2025;392: 2193–202. doi:10.1056/NEJMoa2414108
11. Martinez FJ, Wijsenbeek MS, Raghu G, et al. Phase 2B study of inhaled RVT-1601 for chronic cough in idiopathic pulmonary fibrosis: A multicenter, randomized, placebo-controlled study (SCENIC trial). Am J Respir Crit Care Med. 2022;205: 1084–92. doi:10.1164/rccm.202106-1485OC
12. Dutta P, Funston W, Mossop H, et al. Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis. Thorax. 2019;74: 346–53. doi:10.1136/thoraxjnl-2018-212102
13. Vigeland CL, Hughes AH, Horton MR. Etiology and treatment of cough in idiopathic pulmonary fibrosis. Respir Med. 2017;123: 98–104. doi:10.1016/j.rmed.2016.12.016
14. Carvalho da Silva MA, Mouro de Santos Rolo RM, Pereira Catarata MJ, de Sousa Antunes Dias Padrão EF. Cough in idiopathic pulmonary fibrosis: what is new. Breathe (Sheff). 2025;21: 240176. doi:10.1183/20734735.0176-2024
15. Maher TM, Avram C, Bortey E, et al. Nalbuphine tablets for cough in patients with idiopathic pulmonary fibrosis. NEJM Evid. 2023;2: EVIDoa2300083. doi:10.1056/EVIDoa2300083
16. Molyneaux PL, Mogulkoc N, Gunen H, et al. Oral nalbuphine in idiopathic pulmonary fibrosis-associated cough: The CORAL randomized clinical trial. JAMA. 2026. doi:10.1001/jama.2025.26179
17. Yaksh T, Wallace M. Opioids, Analgesia, and Pain Management. McGraw Hill Medical. Available: https://accessmedicine.mhmedical.com/content.aspx?sectionid=170269577&bookid=2189
18. Higgins J, Welch V. Cochrane Handbook for Systematic Reviews of Interventions. [cited 25 Dec 2025]. Available: https://www.cochrane.org/authors/handbooks-and-manuals/handbook
19. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; l4898. doi:10.1136/bmj.l4898
20. Guyatt G, Agoritsas T, Brignardello-Petersen R, et al. Core GRADE 1: overview of the Core GRADE approach. BMJ. 2025;389: e081903. doi:10.1136/bmj-2024-081903
21. Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343: d4002. doi:10.1136/bmj.d4002
22. Higgins JPT, White IR, Anzures-Cabrera J. Meta-analysis of skewed data: combining results reported on log-transformed or raw scales: META-ANALYSIS OF SKEWED DATA. Stat Med. 2008;27: 6072–92. doi:10.1002/sim.3427
23. Chapter 23: Including variants on randomized trials. [cited 3 Mar 2026]. Available: https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-23
24. Schelfhout J, Nguyen AM, Birring SS, et al. Validation and meaningful change thresholds for an objective cough frequency measurement in chronic cough. Lung. 2022;200: 717–24. doi:10.1007/s00408-022-00587-2
25. Raj AA, Pavord DI, Birring SS. Clinical cough IV:what is the minimal important difference for the Leicester Cough Questionnaire? Handb Exp Pharmacol. 2009; 311–20. doi:10.1007/978-3-540-79842-2_16
26. Lee J, White E, Freiheit E, et al. Cough-specific quality of life predicts disease progression among patients with interstitial lung disease: Data from the pulmonary fibrosis foundation patient registry. Chest. 2022;162: 603–13. doi:10.1016/j.chest.2022.03.025
27. Martinez FJ, Afzal AS, Smith JA, et al. Treatment of persistent cough in subjects with idiopathic pulmonary fibrosis (IPF) with gefapixant, a P2X3 antagonist, in a randomized, placebo-controlled clinical trial. Pulm Ther. 2021;7: 471–86. doi:10.1007/s41030-021-00162-9
28. McGarvey LP, Birring SS, Morice AH, et al. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022;399: 909–23. doi:10.1016/S0140-6736(21)02348-5
29. Boulet L-P, Coeytaux RR, McCrory DC, et al. Tools for assessing outcomes in studies of chronic cough: CHEST guideline and expert panel report. Chest. 2015;147: 804–14. doi:10.1378/chest.14-2506
30. van Manen MJG, Birring SS, Vancheri C, et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017;50: 1701157. doi:10.1183/13993003.01157-2017
31. Lee KK, Savani A, Matos S, Evans DH, Pavord ID, Birring SS. Four-hour cough frequency monitoring in chronic cough. Chest. 2012;142: 1237–43. doi:10.1378/chest.11-3309
32. Bacci ED, O’Quinn S, Leidy NK, Murray L, Vernon M. Evaluation of a respiratory symptom diary for clinical studies of idiopathic pulmonary fibrosis. Respir Med. 2018;134: 130–8. doi:10.1016/j.rmed.2017.11.011
33. Ekström M, Ferreira D, Chang S, et al. Effect of regular, low-dose, extended-release morphine on chronic breathlessness in chronic obstructive pulmonary disease: The BEAMS randomized clinical trial: The BEAMS randomized clinical trial. JAMA. 2022;328: 2022–32. doi:10.1001/jama.2022.20206
34. Morice AH, Menon MS, Mulrennan SA, et al. Opiate therapy in chronic cough. Am J Respir Crit Care Med. 2007;175: 312–5. doi:10.1164/rccm.200607-892OC
35. Birring SS, Dicpinigaitis PV, Maher TM, et al. Kappa and mu opioid receptors in chronic cough: Current evidence and future treatment. Lung. 2025;203: 62. doi:10.1007/s00408-025-00812-8
Downloads
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
